San Diego Clinical Trials

Curriculum Vitae - Mo Bidair, MD

EDUCATION

1990 – 1994, Residency in Urology, University of California San Diego, CA
1988 – 1990, Residency in General Surgery, University of California San Diego, CA
1984 – 1988, MD, CM Degree, McGill University, Faculty of Medicine, Montreal, Canada
1980 – 1984, A.B. Honors Cum Laude in Engineering & Applied Sciences, Specialization in Computer Sciences, Harvard University, Cambridge, MA

PROFESSIONAL POSITIONS

2008 – Present, Medical Director, San Diego Clinical Trials, La Mesa, CA
2002 – 2008, Medical Director, Center for Urological Research, La Mesa, CA
1997 – Present, Urologic Surgery Private Practice Partnership. Alvarado-La Mesa Urology, San Diego, CA
1998 – 2002, Director, Research Division, San Diego Urology Center, San Diego, CA
1998 – 2001, Medical Director, Clinical Research Medical Associates, San Diego, CA
1994 – Present, Assistant Clinical Professor of Surgery/Urology, Division of Urology, University of California, San Diego, CA
1998 – 1999, President, San Diego Urologic Society
1995 – 1997, Chief, Section of Urology, Veteran Affairs Medical Center, La Jolla, CA
1994 – 1995, Staff Physician, Veterans Affairs Medical Center, La Jolla, CA

BOARD CERTIFICATION

Board Certification, Diplomate, American Board of Urology, 1996

CERTIFICATIONS AND LICENSES

Diplomate, American Board of Medical Examiners, July 3,1989. Certificate # 351817
Basic Microsurgery Training, San Diego Microsurgical Institute, and Training Center. August 5-9, 1991
Advanced Laparoscopy for the Urologist, Laser Research Center, Cedars-Sinai Medical Center. January 16, 1993
National Lithotripsy Training Program for Performance of Renal Shock Wave Lithotripsy Using the Siemens Lithostar. September 1993
Contigen Implant Training Program University of California, San Diego. March 14, 1994
Lasers in Urology, American Urological Association, Texas Medical Center, Houston TX. May 13-14, 1995
Techniques in Ureteroscopy, University of California, San Diego. January 20, 1996
TransUrethral Needle Ablation (TUNA) System Certification, 1997

HONORS AND AWARDS

University of California, San Diego, School of Medicine, Department of Surgery Chairman 's Prize for Outstanding Achievement as a Resident, 7/1/90 – 6/30/94
Abbott Laboratories Award for Excellence in Basic Science Research, 1993 – 94
Abbott Laboratories Award for Excellence in Teaching, 1993 – 94
Abbott Resident's' Award for Excellence in Basic Science Research, 1991 – 92
Aga Khan Foundation (Switzerland) Scholarship for Medical School Tuition and Expenses, 9/85 – 6/88
Aga Khan Travel Award for Primary Care Medicine in Nairobi Kenya, 2/88 – 3/88
Sir P. Reathy Scholarship, Dr. E.M. Trisher Scholarship (McGill University), 1985 – 86
Harvard College Scholarship for Academic Achievement, 1982 – 84
Harvard College Dean's List, 1980 – 84

ADDITIONAL WORK EXPERIENCE

1997 – 1999, VRG International, Sub Specialty Investigator on Clinical Trials.
1985 – 1985, McGill Medical School, Research Bursary Program. Designed, Programmed & Developed Computer Database for Analyzing Data by Researchers at the Polypeptide Labs at McGill.
1983, Harvard University, Head Teaching Fellow. Selected and Supervised 20 Teaching Fellows for Introductory Computer Science Course. Worked Closely with the Professor to Compose Weekly Assignments and Exams in Addition to Teaching a Section of 10 Students.
1982, Teaching Fellow for Course Described Above.
1982 – 1984, Harvard Science Center. Systems Operator/Programmer and User Consultant for Harvard College Computer Facilities.
1983, 1984, Harvard Summer School, Resident Advisor. Live-in Counselor for 25 Summer School Students.
1979 – 1980 Lester Pearson College, Scuba Diving Instructor. In Groups of 4 In the Classroom, Pool and Open Sea British Sub-Aqua Club Instructor.

LANGUAGES

French, Spanish, Arabic

MEMBERSHIP IN PROFESSIONAL SOCIETIES

American Urological Association Active Member
American Urological Association Western Section Member
American Medical Association Member
San Diego County Medical Association Member
San Diego County Urologic Society, Positions Held:
President 8/98-8/99; Vice-President 8/97-8/98; Secretary/Treasurer 8/95-8/97.

INSTRUCTIONAL COURSES

Organized and Conducted Laparoscopy Course with Lab for Surgery Residents. UCSD Medical Center, San Diego, CA, January 6, 1996.

Organized Prostate Screening Day at Grossmont Hospital, La Mesa, CA, September 6, 1997.

COMMlTTEES

Arrangements Committee, AUA Western Section, 72nd Annual Meeting,
San Diego, CA. 1996
Cancer Committee, Grossmont Hospital 1/98

EDITORIAL POSITIONS

Consultant, Journal of Urology 1996 - 1997

PRESENTATIONS

Bidair, M, Jones, S.M. and Kaplan, GW.: Infantile hypertrophic pyloric stenosis and hydronephrosis: Is there an association? Presented at the 87th Annual American Urological Association Meeting, Washington, DC, May 10-14,1992.

Brodak, P.P., Teichman, J.M.TL, Bidair, M. and Juma, S.: Videourodynamic evaluation of tapping as a method of bladder emptying. Presented at the 87th Annual American Urological Association Meeting, Washington, DC, May 10-14, 1992.

Brodak, P.P., Bidair, M., Joseph, A. and Juma, S.: Leak point pressure in the evaluation of sphincterotomy: Is it effective? Presented at the International Forum of Paraplegia, 31st Annual Scientific Meeting, Barcelona, Spain, Sept. 10-14, 1992.

Bidair, M., Brodak, P.P., Joseph, A., Juma S., Szollar, S.: Electromagnetic evoked response of the detrusor and striated sphincter motor pathways, Presented at the International Forum of Paraplegia, 31st Annual Scientific Meeting, Barcelona, Spain, Sept. 10-14, 1992.

Bidair, M., Demby, A.M.: Polyorchidism: Magnetic resonance imaging (MRI) diagnosis avoided the need for exploration. A case report and literature review. Presented at the 68th Annual Meeting of the Western Section, AUA, Maui, Hawaii, October 25-30, 1992.

Bidair M., Brodak, P.P., Teichnan, J.M.H. and Juma, S. Transrectal ultrasound urodynamics versus fluoroscopy videourodynamics. Presented at the 68th Annual Meeting of the Western Section, AUA, Maui Hawaii, October 25-30, 1992.

Parsons, C.L., Bidair, M. and Stein P.C.: Simple test to measure epithelial permeability in interstitial cystitis patients. Presented at 89th Annual AUA Meeting, San Francisco, CA, May 14-19,1994.

Trinh, T., Simonian, J., Vigil, S., Chin, D. and Bidair, M,: Continuous versus intermittent bladder irrigation of Amphotericin B for the treatment of candiduria. Presented at Western States Conference for Pharmacy Residents, Fellows and Preceptors, Monterey, CA. May 15-18, 1994.

Bidair, M.: Treatment of BPH. Presented at AUA Allied Southern California Chapter meeting, San Diego, CA. October 1, 1994.

Bidair, M.: Transperineal cryoablation for prostate cancer. Presented at Center for Health Care, Rancho Bernardo, CA. November 2, 1994.

Masson, D., Bidair, M. and Schmidt, J.D., Epidural abscess from retroperitoneal torsion of testis in an adult. Presented at Annual Meeting of the Southern California Chapter, American College of Surgeons, Indian Wells, CA. January 21, 1995.

Bidair, M.: Treatment options in the management of BPH, Presented for Roerig Pharmaceutical, San Diego, CA. April 11, 1995.

Masson, D., Bidair, M., Shabaik, A., Wilson, S. and Schmidt, J.D.: Pathologic changes in prostate biopsies following cryoablation therapy. Presented at 90th Annual Meeting of the AUA, Las Vegas, NV. April 23-28, 1995.

Patel, B.G., Lee, S. and Bidair, M.: How to manage the retained ureteral stent. Presented at 71st Annual Western Section AUA Meeting, Scottsdale, AZ. November 5-9, 1995.

Patel, B.G., Tay, R.P. and Bidair, M.: Metastatic melanoma to the testes. Presented at 71st Annual Western Section AUA Meeting, Scottsdale, AZ. November 5-9, 1995.

Walker, C.J. and Bidair, M.: Neurogenic bladder associated with segmental myoclonus: A case report. Presented at 71st Annual Western Section AUA Meeting, Scottsdale, AZ. November 5-9, 1995.

Schmidt K.J., Patel, B.G. and Bidair, M.: Comparison of fluoroscopic and visual leak point pressures in spinal cord injury patients. Presented at 72nd Annual Western Section, American Urological Association meeting, San Diego, CA.
July 28 - August 1, 1996.

Schmidt.. J.D., Parsons, C.L. and Bidair, M.: Transperineal cryoablation for prostate cancer: Current results and management of complications. Presented at 72nd Annual Western Section, American Urological Association Meeting,
San Diego, CA. July 28 - August 1, 1996.

Bernstein, I.B. and Bidair, M.: Extraperitoneal laparoscopic bladder diverticulectomy. Presented at 72nd Annual Western Section, American Urological Association meeting, San Diego, CA. July 28 - August 1, 1996.

Singh, K.J. and Bidair, M.- Utility of routine urodynamic studies in asymptomatic spinal cord injury patients. Presented at 72nd Annual Western Section, American Urological Association meeting, San Diego, CA. July 28 - August 1, 1996.

Singh, K.J., Patel, B.G. and Bidair, M.: Comparison of fluoroscopic and visual leak point pressures in spinal cord injury patients. Presented at 72nd Annual Western Section, American Urological Association meeting, San Diego, CA. July 28 – August 1, 1996.

Bidair, M., Hulting, S.M., Isaacson, J.D., Sleep, D.J., Frankel, J.M.:
Effect of Atrasentan on Bone Pain in Hormone-Refractory Prostate Cancer Patients with Bone Metastases. Presented at 79th Annual Western Section, American Urological Association meeting, Vancouver, B.C., Canada. June 30, 2005.

PUBLISHED ABSTRACTS

Bidair, M, Jones, S.M. and Kaplan, G.W.: Infantile hypertrophic pyloric stenosis and hydronephrosis: Is there an association? J Urol 147(4): 383A, 1992.

Brodak, P.P., Teichman, J.M.H., Bidair, M. and Juma, S.: Videourodynamic evaluation of tapping as a method of bladder emptying. J Urol 147(4). 437A, 1992.

Masson, D., Bidair, M, Shabaik, A., Wilson, S. and Schmidt J.D.: Pathologic changes in prostate biopsies following cryoablation therapy. J Urol 153: 484A, 1995.

PUBLICATIONS

Bidair, M., Kalota, S.J. and Kaplan, G.W.: Infantile hypertrophic pyloric stenosis and hydronephrosis: Is there an association? J Urol 150: 153-5, 1993.
Bidair, M., Teichman, J..M.H., Brodak, P.P. and Juma, S.: Transrectal ultrasound
urodynamics (TRUSU). Urology 42(6)-. 640-45, 1993.

Brodak, P.P., Bidair, M., Joseph A. and Juma, S.: Magnetic stimulation of the sacral roots. Neurourol Urodyn 12: 533-40, 1993.

Parsons, C.L., Stein, P.C., Bidair, M. and Lebow, D.: Abnormal sensitivity to intravesical potassium in interstitial cystitis and radiation cystitis. Neurourol Urodyn 13:515-520, 1994.

Tay, H., Bidair, M., Gilbaugh III, J.H. and Schmidt, J.D.: Primary yolk sac tumor of the prostate. A case report of a rare disease and literature review. J Urol 153: 1066-1069, 1995.

Shabaik, A., Wilson, S., Bidair, M., Masson, D., Schmidt, J.D. and Parsons, C.L.: Pathologic changes in prostate biopsies following cryoablation therapy of prostate carcinoma. J Urol Path 3: 183-193, 1995.

Trinh, T., Simonian, J., Vigil, S., Chin, D. and Bidair, M.: Continuous versus intermittent bladder irrigation of amphotericin B for the treatment of candiduria, J Urol 154:. 2032-34, 1995.
Walker, C., Niku, S.D., Bidair, M. and Schmidt, J.D.: Ogilvie's syndrome after distal ureterectomy-. diagnosis and treatment. Contemp Surj 49(3): 148-151, 1996.

Parsons, C.L. and Bidair, M.: The bladder in multiple sclerosis. in Multiple Sclerosis, 1 st Edition, Chapt. 22, Raine et al. (eds). Chapman & Hall Ltd., London. 1997.

Gaylis FD, Bastuba M, Bidair M, Friedel WE: Ureteral Dilation Using a Tapered Dilator: A Cost Effective Approach. Journal Of Endourology 14 (5): 447-449, 6/2000.

RESEARCH EXPERIENCE

Investigator: Phase III Randomized Study of a Single Adjunctive Instillation of Intravesical Study Medication versus No Adjunctive Therapy Immediately Following Transurethral Resection in Patients with Multiple Superficial (Ta/T1) Bladder Tumors.
Protocol A9601. 09/1996

Sub-Investigator: A Phase II Study: Intravesical Study Medication in Patients with Carcinoma in Situ of the Bladder who have Failed or Have Recurrence Following Treatment with BCG.
Protocol A9302. 09/1996

Sub-Investigator: A Phase II Study: Intravesical Study Medication in Patients with Transitional Cell Carcinoma of the Bladder.
Protocol A9303. 09/1996

Sub-Investigator: A Randomized, Double-Blind, Placebo-Controlled, Two Year Group Study of the Efficacy and Safety of Study Medication 0.5mg in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia. Followed by a Two Year Open Label Treatment Phase
Protocol ARIA3001. 01/1997

Sub-Investigator: A Multi-Center, Open-Label, Dose Escalation Study of the Safety and Therapeutic Effects of Study Medication-Depot, Administered as an Intramuscular (IM) or Subcutaneous (SC) Injection, in Prostate Cancer Patients who are Candidates for Initial Hormonal Therapy and Prospective Concurrent Control Study.
Protocol 149-97-04. 11/1997

Sub-Investigator: A Phase III, Efficacy and Safety Study Comparing Escalating Doses of Study Medication SL to 5mg or 6mg Doses of Study Medication SL or Placebo in the Treatment of Male Erectile Dysfunction.
Protocol M97-763. 12/1997

Sub-Investigator: A Phase III, Long-Term, Open-Label, Flexible Dose, Safety Extension Study of Study Medication SL Tablets in the Treatment of Male Erectile Dysfunction.
Protocol M97-682. 03/1998

Sub-Investigator: A Phase III, Safety and Efficacy Study of Two Fixed Doses of Study Medication SL Tablets versus Placebo in the Treatment of Male Erectile Dysfunction in Patients with Controlled Diabetes.
Protocol M97-804. 04/1998

Investigator: An Extension Study to Evaluate the Safety and Tolerability of Study Medication in Subjects with Hormone Refractory Adenocarcinoma of the Prostate.
Protocol M97-739. 04/1988

Investigator: Dose Ranging Study Comparing Best Medical Therapy With and Without Study Medication for the Treatment of Men with Asymptomatic Hormone Refractory Adenocarcinoma of the Prostate.
Protocol M96-594. 04/1998

Investigator: Dose Ranging Study Comparing Best Medical Therapy With and Without Study Medication for the Treatment of Pain in Men with Symptomatic Hormone Refractory Adenocarcinoma of the Prostate.
Protocol M96-500. 04/1998

Sub-Investigator: A Phase III, Long-Term, Open-Label, Flexible Dose, Safety Extension Study of Study Medication SL Tablets in a Special Population for the Treatment of Male Erectile Dysfunction.
Protocol M97-793. 05/1998

Sub-Investigator: Study Medication Versus Placebo in the Relief of Stress Incontinence.
Protocol F1J-MC-SAAW(c). 08/1998

Sub-Investigator: A Phase II Safety Study of 5mg Study Medication SL Tablets versus Placebo in the Treatment of Patients Diagnosed with Male Erectile Dysfunction Following A Bilateral Nerve-Sparing Radical Retropubic Prostatectomy.
Protocol M97-788 09/1998

Sub-Investigator: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Study Medication in the Treatment and Modification of Progression of Benign Prostatic Hyperplasia.
Protocol ARIB3003 09/1998

Sub-Investigator: A Phase III, Multi-Center, Open-Label, Randomized Study of Study Medication vs. LupronÂ® In Patients with Prostate Cancer Who Are Candidates for Initial Hormonal Therapy.
Protocol 149-98-03. 10/1998

Sub-Investigator: A Phase III Efficacy and Safety Study of Three Fixed Doses of Study Medication SL Tablets 2mg and 5mg Versus Placebo in the Treatment of Male Erectile Dysfunction.
Protocol M98-941. 12/1998

Sub-Investigator:: A Multi-Center Study of Study Medication In Patients with Prostate Cancer in Whom GnRH Agonists are Contraindicated. Clinical
Protocol 149-98-04 04/1999

Investigator: "A Phase III, Open-Label, Multi-Center Study Of The Efficacy And Safety Of Leuprolide Acetate For Depot Suspension 7.5 Mg (30 Day) In Patients With Advanced Prostate Cancer".
Protocol OL-002. 06/1999

Sub-Investigator: Long Term Compliance of Oral Supplements by Oncology Outpatients in Need of Nutritional Support.
Protocol #7081 Study # 9901. 7/99

Sub-Investigator: Quality of Life (QoL) in Patients Treated with Tolterodine (Detrol) for Overactive Bladderâ€‚ CTN: 583URO0087-070 08/1999

Sub-Investigator: A Phase 3, Multi-Center, Open-Label Randomized Study of Study Medication 100 mg IM vs Lupron Deport 7.5mg IM in Patients with Prostate Cancer Who Are Candidates for Initial Hormonal Therapy.
Protocol 990744/149-99-03. 10/1999

Investigator: A Multi-Center, Double-Blind Study to Compare the Safety and Efficacy of Levofloxacin to that of Ciprofloxacin in the Treatment of Chronic Prostatitis.
Protocol CAPSS-101, Phase 3B. 1/2000

Investigator: Long Term Compliance of Oral Supplements by Oncology Outpatients in Need of Nutritional Support.
Project #7081 Study # 9901.

Sub-Investigator: A 12-Week Safety and Efficacy Study of Oral Study Medication Versus Placebo in Subjects with Overactive Bladder
Protocol M98-946 01/2000

Sub-Investigator: A Multi-Center, Double-Blind Study to Compare the Safety and Efficacy of Levofloxacin to that of Ciprofloxacin in the Treatment of Chronic Prostatitis.
Protocol CAPSS-101, Phase 3B. 1/2000

Sub-Investigator: A Rollover, Multi-Center, Open-Label, Maintenance Study of Patients with Prostate Cancer Who were Previously Treated with Study Medication 50 mg or 100 mg IM.
Protocol 990789/149-99-04 2/2000

Sub-Investigator: A Phase 3 Study of the Efficacy of Study Medication (a Protein Kinase C Beta Inhibitor) in Males with Diabetes and Erectile Dysfunction.
Protocol B7A-MC-MBCC 3/2000

Sub-Investigator: A 12 Week Phase III, Placebo-Controlled Study of Men with Symptomatic BPH.
Protocol M99-097. 03/2000

Investigator: A Randomized Clinical Trial Comparing Goserelin Acetate 3.6 mg Depot and Goserelin Acetate 10.8 mg Depot in Subjects with Prostate Cancer for Whom Therapy is Indicated.
Protocol 9393IL/0028 5/2000

Sub-Investigator: A Long-Term, Open Label Extension Trial Evaluating the Safety and Efficacy of Study Medication in Subjects with Benign Prostatic Hyperplasia.
Protocol M00-179. 06/2000

Investigator: Satisfaction and Experience with Testosterone Replacement Therapy.
Protocol UMD-00-067 08/2000

Investigator: Development of a Molecular Classification of Prostate Cancer.
Protocol SKCC 9905 08/2000

Sub-Investigator: A Six-Month, Open Label, Fixed Dose Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Endocrine Efficacy of Two Doses of LA-2550 22.5 mg In Patients with Advanced Prostate Cancer.
Protocol AGL 9909 09/2000

Investigator: Phase III Randomized, Double-Blind Study of DMFO vs. Placebo in Low Grade Superficial Bladder Cancer.
Protocol DMFO 0341-A2 9/2000

Sub-Investigator: An Eight-Month, Open-Label, Fixed-Dose Study to Evaluate the Safety, tolerance, Pharmacokinetics and Endocrine Efficacy of Two Doses of LA2575 30mg in Patients with Advanced Prostate Cancer.
Protocol AGL0001 01/2001

Sub-Investigator: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Fixed-Dose, Multi-Center Study to Assess Efficacy and Safety of Daily Oral Administration of Study Medication vs Placebo in Male and Female Subjects with Overactive Bladder.
Protocol 905-CL-013 01/2001

Sub-Investigator: A Double-Blind Randomized Parallel Group Study of Alfuzosin 10 mg QD versus Placebo in the Management of Acute Urinary Retention in Patients with a First Episode Due to BPH.
Protocol Alfaurus EFC4428 03/2001

Sub-Investigator: Long-Term, Efficacy and Safety of Alfuzosin 10 mg OD on the Risk of Acute Urinary Retention and the Need for Surgery in Patients with BPH.
Protocol Altess EFC4485 03/2001

Sub-Investigator: Prospective, Randomized, Double-Blind, Multi-Center, Comparative Trial to Evaluate The Efficacy and Safety of Ciprofloxacin Once Daily Modefied Release (CIPRO MR) 500mg Tablets for 3 days versus Conventional Ciprofloxacin 250mg Tablets BID for 3 days in The Treatment of Patients With Uncomplicated Urinary Tract (uUTI) Infections.
Protocol 100346 6/2001

Investigator: A Phase III, Extension Study to Evaluate the Safety of 10mg Atrasentan in Men with Hormone Refractory Prostate Cancer.
Protocol MOO-258 06/2001

Sub-Investigator: Open Label Use of A Unique Testosterone Topical Gel Formulation in Males with an Original Baseline Testosterone Level <300ng/dl.
Protocol AUX-203.01 06/2001

Investigator: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of 10mg Atrasentan in Men with Metastatic, Hormone Refractory Prostate Cancer.
Protocol MOO-211 06/2001

Sub-Investigator: An Open-Label, Long-term Tolerability Study of Daily Oral Administration of 10 mg YM905 in Male and Female Subjects with Overactive Bladder.
Protocol YM905-CL-016 07/2001

Investigator: A Phase III, Double-Blind, Placebo Controlled Study of the Safety and Efficacy of 10mg Atrasentan in Men with Non-Metastatic , Hormone Refractory Prostate Cancer.
Protocol MOO-244 08/2001

Sub-Investigator: A Four-Week â€œProof of Conceptâ€ Study to Determine the Safety, Tolerability and Efficacy of Oral SB223412 in Patients with Symptoms of Urinary Urgency and Frequency with or without Incontinence.
Protocol SB 223412/020 09/2001

Investigator: A Phase III, Randomized, Double Blind, Placebo Controlled Study of the safety and efficacy of 10 mg Atrasentan in Men with Metastatic, Hormone-Refractory Prostate Cancer.
Protocol MOO-211 09/2001

Sub-Investigator: Plasma Isolation Study-FastPackâ„¢ PSA Immunoassay.
Protocol SDUC001 03/2002

Sub-Investigator: A Phase 3B, Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel Group Study of Darfenacin in Subjects with Overactive Bladder.
Protocol A1371047 04/2002

Investigator: A Phase II Study, Evaluating the safety and efficacy of Atrasentan (ABT-627) in Men with Hormone NaÃ¯ve Prostate Cancer that are Exhibiting Early Signs of Biochemical Failure.
Protocol MO1-366 04/2002

Investigator: An Open Label Trial on the Effect of I.V. Zometa 4mg on Bone Mineral Density in Hormone Sensitive Prostate Cancer Patients.
Protocol CZOL446E US24 07/2002

Sub-Investigator: A twelve week flexible dose regimen of Vardenafil compared to placebo in male erectile dysfunction subjects of broad etiology previously unresponsive to Viagra therapy by history.
Protocol SB-782528 10/2002

Sub-Investigator: Phase II Overactive Bladder study to investigate the safety of three different doses of sustained release Festerodine in subjects with overactive bladder showing either involuntary detrusor contractions or normal findings during baseline urodynamic assessment.
Protocol SP668 11/2002

Sub-Investigator: MedTap Pharmacueticals 02/2003nter Study of Darifenacin in Subjects with Over-Active Bladder.
Protocol A1371042 12/2002

Sub-Investigator: A Randomized, Double-Blind, Placebo Controlled, Parallel Group of Study of Efficacy, and Safety of Dutasteride 0.5 mg Administered Once Daily for Four Years to Reduce the incidence of Biopsy-Detected Prostate Cancer.
Protocol ARIA4006 01/2003

Sub-Investigator: Phase III, Open-Label, Single Dosage, Uncontrolled, Multi-center Study Conducted in Men with Prostatic Adenocarcinoma. Two doses of 45mg Depot Lupron given 26 weeks apart.
Protocol C02-008 02/2003

Sub-Investigator: A Randomized Double-Blind, Four Month Study to Compare the Tolerability and Efficacy of Flexible Dose Vardenafil versus Placebo in Men with Depression and Erectile Dysfunction.
Protocol 10621 02/2003

Sub-Investigator: Questionnaire Study for Patients with Over-Active Bladder including Presence of Urinary Urgency with or without Urinary Incontinence.

Sub-Investigator: A randomized, double-blind, parallel-group, placebo-controlled study evaluating the efficacy, safety and reliability of 20 mg vardenafil administered for 12 weeks compared to placebo in subjects with erectile dysfunction and a demonstrated successful first response to 20 mg vardenafil.
Protocol SB 782528/032 05/2003

Investigator: The effect of Zometa Compared to Placebo on Bone Mineral Density in Patients Undergoing Androgen Deprivation Therapy.
Protocol CZOL446G US 45 05/2003

Investigator: A Double-Blind, Randomized. Placebo-Controlled Trial Of ELMIRON For the Treatment of Chronic-Non-Bacterial Prostatitis.
Protocol CAPPS-263 06/2003

Sub-Investigator: Study of Duloxetine HCI in Women of Different Demographics and Co-Morbidities with Stress Urinary Incontinence: Evaluation of Efficacy and Safety.
Protocol F1J-US-SBCD 01/2004

Sub-Investigator: Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT).
Protocol 20010184 01/2004

Sub-Investigator: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Theraapy for Non-metastatic Prostate Cancer.
Protocol AMG 162 20040138 01/2004

Investigator: Prospective, Observational Registry and Patient Survey of the Management of Men with Symptomatic Benign Prostatic Hyperplasia (BPH)
Protocol L8890 01/2004

Investigator: A Multi-Center, Open-Label, Non-Controlled Study to Demonstrate the Safety and Hormonal Efficacy of GS-121
Protocol GS-121-01 05/2004

Investigator: An Open-Label, Multicenter study to assess the efficacy and safety of daily oral administration of 5 and 10 mg Vesicare.
Protocol 905-UC-006 09/2004

Investigator: Prospective, Observational Registry of the Management of Men with Prostate Cancer and a Rising PSA-PCA Registry
Protocol L8891 12/2004

Investigator: Phase III, Open-Label, Multi-Center, Safety and Efficacy Study of Oakwood Laboratories Leuprolide Acetate in patients with Advanced Prostate Cancer.
Protocol OL-007 12/2004

Investigator: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients with Metastatic Prostate Cancer Commencing Hormonal Therapy
Protocol GU02-41 12/2004

Investigator: A randomized, double-blind placebo-controlled, multicenter efficacy and safety study of Toremifene Ditrate for the prevention of bone fractures in men with prostate cancer on androgen deprivation therapy
Protocol G300203 12/2004

Sub-Investigator: An open-label, large simple usual care study of the effect of adding Rofecoxib 50 mg to a regimen of selected Opioid analgesic PRN in patients undergoing selected outpatient Surgical Procedures
Protocol 0302-0 12/200

Investigator: A Phase 2 randomized, double-blind, controlled study to evaluate the safety and efficacy of PROSTVAC-VF/TRICOM in combination with GM-CSF in patients with Androgen-Independent Adenocarcinoma of the prostate
Protocol TBC-PRO-002 12/2004

Sub-Investigator: Multi-center randomized double-blind, placebo-controlled parallel study of men with mild to moderate ED to evaluate the efficacy of Viagra 8 hours post dose
Protocol A1481230

Sub-Investigator: A randomized, double-blind, placebo-controlled, parallel arm, multi-center trial assessing the effect of daily treatment of Vardenafil 20mg of Sildenafil 100mg compared to placebo on spermatogenesis, mean sperm concentration, sperm count, morphology, mortality and reproductive hormones in healthy males or males with mild erectile dysfunction
Protocol BAY38-9456 03/2005

Sub-Investigator: A randomized, double-blind, placebo controlled, multi-center, phase 3 study of Rosuvastatin (CRESTOR) 20mg in the primary prevention of cardiovascular events among subjects with low levels of LDL-cholesterol and elevated levels of C-reactive protein
Protocol 4522US/0011 03/2005

Investigator: A multi-center, double-blind, randomized study to compare the efficacy and safety of Levofloxacin 750mg once daily for 5 days versus ciprofloxacin twice daily for ten days in the treatment of complicated urinary tract infection or acute Pyelonephritis
Protocol RWJ-25213-097 04/2005

Sub-Investigator: An open-label, multi-centre, randomized parallel group comparison of efficacy and safety of Degarelix three-month depot in three different dosing regimens of 240mg (40mg/mL) and 240mg (60mg/mL) in patients with prostate cancer requiring Androgen Ablation Therapy
Protocol FE200486 CS15 04/2005

Investigator: A protocol for blood and urine sample collection from urologically referred subjects being evaluated for the presence of prostate cancer and other prostate conditions and disease to aid in the study of in Vitro diagnostic devices
Protocol UREF COLL 04/2005

Sub-Investigator: Study of Duloxetine HCl in women of different demographic characteristics and co-morbidities with stress urinary incontinence: evaluation of efficacy and safety
Protocol F1J-US-SBCD 05/2005

Investigator: A Phase 3 randomized, open-label study of CG1940 and CG8711 versus Docetaxel and Prednisone in patients with metastatic hormone refractory prostate cancer who are Chemotherapy-NaÃ¯ve
Protocol G-0029 5/2005

Investigator: Tolerablility and safety of Dapoxetine in combination with Tamsulosin
ProtocolC-2004-017-02 Phase 1 Study 5/2005

Investigator: A phase 2, Randomized, Multicenter, Placebo-Controlled, Double-Blind, Dose-Ranging Clinical Trial To Study the Efficacy and Safety of 5, 15 or 25mg/day Cypat (Cyproterone Acetate) for the Treatment of Hot Flashes Following Surgical or Medical Castration of Prostate Cancer Patients
Protocol DR PCA-201

Investigator: A two-arm, open-label, randomized, multicenter pharmacokinetic and long-term safety and study of intramuscular injections of 750MG and 1000MG testosteroneundecanoate in hypoogonadal men
Protocol IP157-001

Investigator: A Randomized, double-blinded, placebo-controlled, parallel group study of the efficacy and safety of Dutasteride 0.5mg administered once daily for four years to reduce the risk of Biopsy-Detectable prostate cancer
Protocol ARI40006

Investigator: A phase II, randomized, placebo-controlled, placebo controlled study of YM672 in the treatment of painful bladder syndrome/ interstitial cystitis
Protocol 672-CL-035

Investigator: A phase III 24-week, randomized, double-blind, placebo controlled, safety and efficacy trial of flibanserin 50 and 100 milligrams each evening in pre-menopausal women with Hypoactive Sexual Desire Disorder (VIOLET)
Protocol 511.74

Sub-Investigator: A Randomized, Double-Blind , Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab on Prolonging Bone Metastasis-Free Survival in Men with Hormone-Refractory Prostate Cancer
Protocol 20050147

Investigator: A Randomized, Double-Blind, Multicenter Study of Denosumab Compared with Zometa in the Treatment of Bone Metastases in Men with Hormone-Refractory Prostate Cancer
Protocol 20050103

Investigator: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Spermatogenesis in Healthy Male Subjects During Administration of BMS-562086
Protocol CN148014

Investigator: A Phase II Randomised, two-way crossover study to compare the steady state pharmacokinetics of testosterone following application of different Testosterone Metered Dose Lotion doses in hypogonadal male subjects
Protocol MTE05

Sub-Investigator: The Durability of Twice-Daily Insulin Lispro Low Mixture Compared to Once-Daily Insulin Glargine when added to ExistingOral Therapy in Patients with Type 2 Diabetes and Inadequate Glycemic Control
Protocol F3Z-US-100V

Investigator: Open Label, Multi-Center study of the efficacy and safety of MCC in the treatment of patients with non-muscle invasive (superficial) bladder cancer at high risk of progression and who are refractory to BCG
Protocol HIS-0611-0602

Investigator: A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 in subjects with symptoms of Overactive Bladder
Protocol 178-CL-047

Investigator: A Randomized Double-Blind, Parallel Group, Active Controlled, Multi Center Long Term Study Assess the Safety and Efficacy YM178 (50mg qd and 100 mg qd) in subjects with symptoms of overactive bladder
Protocol 178-CL-049

Investigator: A Phase 2, Randomized, Double-Blind, Placebo- Controlled, to Evaluate the Safety and Efficacy of MGAWN1 in Subject with Suspected Central Nervous System Infection Due to West Nile Virus
Protocol CP-MGAWN1-02

Investigator: A Phase 3, Randomized, Double- Blind, Placebo- Controlled, Paralled Design Study to Evaluate the Safety and Efficacy of Daily Tadalafil for 12 Weeks in Men with Signs and Symptoms of Benign Prostatic Hyperlasia on Concomitant Alpha1- Andrenergic Blocker Therapy
Protocol H6D-Mc-LVHS

Investigator: A Randomized, Double-Blind, Placebo- Controlled, Parallel Design, Multinational Study to Evaluate the Efficacy and Safety of Tadalafil 2.5 and 5 mg Once symptom of Benign Prostatic Hyperplasia in Men with Both Erectile Dysfunction and Benign Prostatic Hyperplasia
Protocol H6D-MC- LVHR

Investigator: Randomized, Double- Blind, Parallel Group, Placebo-Controlled, Two-Stage Study to Assess the Efficacy and Safety of 3 doses of Crofelelmer Orally Twice Daily for the Treatment of HIV- Associated Diarrhea
Protocol NP303-101

Investigator: A Single Dose, Two Period, Two- Treatment, Two-Sequence Crossover Bioequivalence study of Melphalan 2 mg Tablets under fasted conditions
Protocol MELP-T2-PVFS-1

Investigator: A Phase 3, Randomized, Double- Blind, Placebo Controlled, Multi- Center Study of the Safety and Efficacy of LibiGel® for the treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Protocol TESTW006

Investigator: A Phase 3, Randomized, Double – Blind, Placebo-Controlled, Multi-Center Study of Long Term Safety and Efficacy of LibiGel ® for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women
Protocol TESTW007

Investigator: A Double Blind, Placebo- Controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects with Non-metastaic Prostate Cancer Receiving Denosumab for Bone Loss Due to Andrgoen-Deprivation Therapy
Protocol 20080560

Investigator: Assessment of the Female External Catheter in the Community Setting
Protocol 4773-1

Investigator: A Double- Blind Randomized. Parallel, Placebo- Controlled, Multicenter Study Evaluating the Effect of Treatment with Topically Administered Oxybutynin Gel in Patients with Urinary Frequency, and Urge and Mixed Urinary Incontinence with a Predominance of Urge Incontinence Episodes with an Open-Label Extension
Protocol 20070060

Investigator: An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG 162) in the treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-Metastatic Prostate Cancer
Protocol 20080537

Investigator: Efficacy and Tolerability of Nasobol®, an Intra-Nasal Testosterone Product, for Testosterone Replacement in Hypogonadal Men
Protocol Nasobol 01-2009

Investigator: A Randomized, Multicenter Trial of Oseltamivir [Tamiflu] Doses of 75 mg for 5 or 10 Days Versus 150 mg for 5 or 10 Days to Evaluate the Effect on the Duration of Viral Shedding in Influenza Patients With Pandemic (H1N1) 2009
Protocol NV22155

Investigator: A Randomized, Multicenter, Single Blinded, Parallel Study of the Safety of 100 mg and 200 mg Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged > 13 Years
Protocol NV25118

Investigator: Clinical Evaluation of the PROGENSA(R) PCA3 Assay in Men with a Previous Negative Biopsy Result
Protocol 2009PCA301

Investigator: MAGELLAN - Multicenter, Randomized, Parallel Group Efficacy and Safety Study for the Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients Comparing Rivaroxaban With Enoxaparin
Protocol 12839

Investigator: Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 intraprostatic injections for the Treatment of BPH
Protocol NX02-0118

Investigator: A Phase 3, Randomized, Double-Blind, Multinational, Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus
Protocol CP-MGA-031-03

Investigator: A 24- Week, Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, International Phase 3 Study with a 24-week Extension Period to Evaluate the Safety and Efficacy of Dapaagliflozin 10mg Daily in patients with Type 2 Diabetes who have inadequate Glyaemic control on a DPP-4 Inhibitor (Sitagliptin) Alone or in Combination with Metformin
Protocol D1690C00010

Investigator: Evaluation of the Content of Validity of the Benign Prostatic Hyperplasia Impact Index (B-II) in Patients with Mild to Moderate Benign Prostatic Hyperplasia
Protocol BII-001-A01

Investigator: A Multicenter, randomized, double-blind, placebo-controlled, parallel group, repeated-dose study to evaluate the efficacy, safety, tolerability and pharmacokinetics of three different dosing regimens of inhaled indacaterol maleate in patients with persistent asthma
Protocol CQAB149B2223

Investigator: PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sachet 6g/day (mesalazine, mesalamine) with placebo
Protocol FE 999904-CS05

Investigator: Effect of Udenafil on Spermatogenesis: A Double-Blind, Randomized, Placebo-controlled, Parallel-group Study
Protocol PR-00110.0

Investigator: A Phase3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone with Placebo Plus Prednisone in Patients with Metastatic Castration- Resistant Prostate Cancer that has progressed during or following Docetaxel-based Therapy
Protocol C21005

Sub-Investigator: Open Label Study of Evaluate the Contraceptive Efficacy and Safety of Norethrindrone Acetate Transdermal Delivery System
Protocol NE0906

Sub-Investigator: A Phase 3B Multicenter, Double- Blind, Randomized withdrawal Efficacy and Safety Study of Pregabalin in the treatment of Patients with inadequately treated painful diabetic peripheral neuropathy
Protocol A0081242

Sub-Investigator: A 12- Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects with Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Protocol ASMP3001

Sub-Investigator: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Clinical Efficacy and Safety of DIAPEP277 in newly diagnosed Type 1 Diabetes Subjects
Protocol 1001